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Aims: The primary objective was to investigate the efﬁcacy of desmopressin orally disintegrating tablet versus placebo
in patients with nocturia. Pharmacodynamics, safety and patient-reported quality of life (QoL) outcomes were also
evaluated. One of several beneﬁts of the new formulation is increased bioavailability. Exploring lower doses allows for
a better evaluation of therapeutic effect versus tolerability. Methods: This was a 4-week, randomized, double-blind
study comparing 10, 25, 50, or 100 mg desmopressin versus placebo in adults with deﬁned nocturia. Results: The
intent to treat population comprised 757 patients experiencing 3 voids/night and a high prevalence of nocturnal
polyuria (90%). Increasing doses of desmopressin were associated with decreasing numbers of nocturnal voids and
voided volume, greater proportions of subjects with >33% reduction in nocturnal voids, and increased duration of ﬁrst
sleep period. The lowest dose reaching statistical signiﬁcance (P < 0.05 vs. placebo) varied by endpoint. Improvements
were clinically meaningful, meaning that patients actually had fewer nightly voids. Post hoc analyses by gender sug-
gested a lower minimum effective dose for women. Desmopressin was generally well tolerated. Reductions in serum
sodium to <125 mmol/L in six women (taking >25 mg desmopressin) and two men (aged 67 and 82) taking 100 mg,
support lower and gender-speciﬁc dosing to reduce the small but clinically signiﬁcant risk of hyponatraemia. Each
void reduced/hour of sleep gained was associated with signiﬁcant improvements in QoL. Conclusions: Desmopressin
orally disintegrating tablet is an effective and well-tolerated treatment for patients with nocturia. Further exploration
of the lower dose range is warranted. Neurourol. Urodynam. 31:441–447, 2012.  2012 Wiley Periodicals, Inc.
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INTRODUCTION
Nocturia is deﬁned as the need to wake to void once or
more per night.1 It is a remarkably prevalent condition2 that
is considered to be clinically signiﬁcant when 2 nightly epi-
sodes are experienced.3,4 Associated chronic fragmentation of
sleep and impaired sleep efﬁciency can have profound conse-
quences for alertness, mood, functioning, cognitive perfor-
mance and work productivity, and may also affect health and
mortality.5
Treatment approaches include conservative management
via ﬂuid restriction, and pharmacological therapy using anti-
cholinergics and/or drugs for benign prostatic hyperplasia
(BPH). However, while these may be effective for daytime
overactive bladder (OAB) or BPH symptoms, they are generally
ineffective for nocturia.6,7
Around 80% of patients with nocturia have nocturnal poly-
uria (NP), which is reported to be associated with decreased
nocturnal secretion of arginine vasopressin (AVP).8–12 This
may be a primary cause of NP or may occur secondary to other
conditions (e.g., sleep apnea and third spacing). Desmopressin
acetate, a synthetic analog of AVP, mimics the action of the
natural hormone, and desmopressin tablets have been shown
to be a well-tolerated and effective treatment for nocturia in
adults with NP in clinical trials.13–17
Desmopressin has most recently been formulated as an orally
disintegrating tablet (oral lyophilisate/melt/orodispersible
formulation) (MINIRIN1 Melt, Ferring Pharmaceuticals A/S,
Copenhagen, Denmark), which is administered sublingually
without water. This formulation is associated with increased
bioavailability, allowing lower dosing than with the original
solid tablets. The primary objectives of this study were to eval-
uate the efﬁcacy and tolerability of desmopressin orally disin-
tegrating tablet versus placebo. The minimum effective dose
(MED) was investigated with a view to further optimizing the
balance between therapeutic effect and tolerability in patients
of all ages.
The study was monitored by an external, independent
Data Safety Monitoring Board and was approved by the insti-
tutional review board or ethics committee for each site. The
study was registered on www.clinicaltrials.gov (NCT00477490,
NCT00615836) on 22 May 2007.
MATERIALS AND METHODS
Patients
Patients were 18 years of age, with an average of 2 voids
per night determined via a 3-day frequency–volume chart
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during screening. They were required to have serum sodium
135 mmol/L, serum creatinine within normal limits, and
estimated glomerular ﬁltration rate 60 ml/mm. Exclusions
included: urinary retention and/or post-void residual volume
>150 ml, or history of urologic malignancies, neurogenic
detrusor activity or current genitourinary tract pathology that
could interfere with voiding. Males were excluded if there
was evidence of bladder outﬂow obstruction (BOO) and/or
urine ﬂow <5 ml/sec, or if surgery for BOO/BPH had been
performed within 6 months. Females with potential for preg-
nancy, use of a pessary for pelvic prolapse, or the presence of
unexplained pelvic mass were excluded. Patients on stable
doses of OAB and/or BPH medication for 3 months could be
included. The study was approved by the institutional review
board/ethics committee for each site. All patients provided
written informed consent.
Study Design and Procedures
This was a 4-week, randomized, double-blind, placebo-
controlled, parallel group, multicenter study, conducted at
78 sites in the USA and Canada between June 2007 and
February 2008.
The trial was powered to demonstrate superiority to
placebo in a step-down approach simultaneously using two
co-primary endpoints. Assuming a baseline nocturia frequency
of three episodes/night, and a placebo response of 0.6–1.2
voids (standard deviation 0.8–1.2), the trial had 80% power
to detect a treatment effect of 0.5 voids. These assumptions
were based on results from the NOCTUPUS trials.14–17
Seven visits were scheduled; three in the ﬁrst week (visits
2–4) and then at weekly intervals (visits 5–7). At screening
(visit 1), investigators recorded demographic data, vital signs,
patient history, and conducted a physical examination, and
took blood and urine for laboratory tests. Where the patient
history led to a clinical suspicion of weak stream or poor emp-
tying, residual volume and Qmax were measured. Patients also
received a diary in which to record the time and volume of all
voids in a 24-hr period for 3 consecutive days.
At visit 2, based on the results of screening and the voiding
diary, eligible subjects were randomized to one of ﬁve treat-
ment groups (placebo or desmopressin 10, 25, 50, or 100 mg)
using a web-based centralized patient randomization system
(WebEZ). Desmopressin and placebo were supplied by Ferring
Pharmaceutical A/S and were indistinguishable with respect
to appearance, smell, taste, and packaging. Treatments were
packaged according to the computer generated randomization
code to ensure that patients, investigators, and the sponsor
remained fully blinded. The tablets were to be taken 1 hr
before bedtime. Randomization was initially stratiﬁed by age
(<65, 65 years) and absence/presence of NP (night-time
urine volume/24-hr urine volume 33%).
Diaries and Questionnaires
At visits 3, 4, and 5 subjects were asked to record times of
nocturnal voids for 3 consecutive nights. Vital signs, history
taking, and blood tests were repeated at each of these visits.
Subjects were instructed to empty their bladder before bed
and drink only to satisfy thirst. Evening intake of diuretic
ﬂuids (such as drinks containing caffeine or alcohol) was espe-
cially discouraged. At visit 6, they recorded the time and vol-
ume of all voids in a 24-hr period for 3 consecutive days. They
also recorded the initial period of undisturbed sleep (time
from falling asleep to ﬁrst nocturnal void) and self-rated sleep
quality (1 [poor]–10 [excellent]). Subjects also completed the
Nocturia Quality of Life (N-QoL) questionnaire (13 statements
in two domains: sleep/energy and bother/concern) at visits
2 and 7. Patients rated each statement from 0 (lowest QoL) to
4 (highest QoL). The raw scores were then transformed into a
standardized score out of 100.
Safety and Tolerability
Adverse events (AEs) were coded by system organ class
and preferred term using MedDRA, and categorized by severi-
ty, seriousness, and likelihood of causal relationship to
study medication rated by the investigator. From the day of
informed consent, AEs were monitored at each visit using a
standard nonleading question such as ‘‘How do you feel since
your last visit?’’ in addition to a speciﬁc question regarding
dry mouth.
Serum sodium was measured at baseline and on Days 4 and
8 and then weekly. These intervals were determined in accor-
dance with previous observations,15,16,18 which demonstrated
that(1) serum sodium decreases usually occur shortly after
treatment initiation,(2) low sodium increases with age and is
rarely seen in subjects <65 years, and(3) low sodium occurs
more frequently in men than women, but is often more severe
in females. The study was therefore designed to document the
early onset of reduction in serum sodium and to ensure the
safety of the participants by closely monitoring sodium levels.
Subjects with values <130 mmol/L at any point were asked
to return the next day for further evaluation. Subjects
with values <125 mmol/L were withdrawn from the study
immediately.
Reductions in serum sodium were captured as a reported AE
of ‘‘hyponatremia’’ or ‘‘blood sodium decreased’’ or as a serum
sodium laboratory value <130 mmol/L. It should be noted
that investigators used their discretion in assigning AEs
and may have assigned an AE of ‘‘hyponatremia’’ or ‘‘blood
sodium decreased’’ with serum sodium 130 mmol/L.
Endpoints
There were two co-primary endpoints: change in mean
number of nocturnal voids from baseline, and proportion of
subjects with >33% reduction in mean number of nocturnal
voids from baseline. Secondary endpoints included change in
diuresis (total and nocturnal volumes), change in initial period
of undisturbed sleep, and change in N-QoL. Safety variables
included AEs and serum sodium values, as well as a standard
battery of blood and urine analyses, vital signs, and physical
examinations.
Statistical Analysis
The intent to treat (ITT) dataset included all randomized
subjects who received 1 dose of study drug and provided 1
post-baseline primary efﬁcacy measure. All subjects who
received 1 dose of the study drug or placebo and had 1
safety assessment were included in the safety analyses.
Change in nocturnal voids was analyzed by analysis of
covariance (ANCOVA) with voids as the dependent variable,
age (<65, 65 years), presence/absence of NP, and treatment
group as independent variables and baseline number of noc-
turnal voids as a covariate. The same covariate and factors
were used in the logistic regression model for the proportion
of subjects with >33% reduction in nocturnal voids. The ﬁrst
period of undisturbed sleep and nocturnal urine volumes
were analyzed in an identical manner.
The impact of change in nocturnal voids on QoL was investi-
gated by an ANCOVA model using change from baseline in
QoL as the dependent variable, main effects for age and NP,
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and change from baseline in nocturnal voids and the baseline
QoL score as covariates. This analysis was performed for the
overall score and for each of the two domains. The impact of
the change in initial period of undisturbed sleep on QoL was
analyzed in a similar manner.
Two-sided tests using a step-down strategy from highest to
lowest dose were used for all efﬁcacy endpoints. Missing val-
ues for nocturnal voids at Days 8, 15, 22, and 28 were imputed
using last observation carried forward.
SAS version 9.1.3 service pack 4 was used.
RESULTS
Patient Disposition and Demographics
Only 799/1,412 subjects were randomized (Fig. 1). The most
common reasons for screening failure were renal insufﬁciency
(15%) and averaging <2 nocturnal voids during screening
(10%). Other reasons included diabetes insipidus (5%), hypona-
tremia (4%), suspected urinary disorders (4%), and uncon-
trolled diabetes mellitus (4%) or hypertension (3%). Reasons
for exclusion were not given in 35% of cases.
The ITT population included 757 subjects and 710 (89%)
completed the study. Across treatment groups, 6–16% of sub-
jects discontinued prematurely. The most common reasons for
discontinuation were withdrawal of consent (4%), AEs (2%),
and lost to follow-up (2%).
Overall, treatment groups were well balanced (Table I).
Change in Mean Number of Nocturnal Voids
A greater decrease in nocturnal voiding was observed with
increasing dose of desmopressin (0.83 to 1.43) (Table II).
Reductions were signiﬁcant versus placebo for 100 mg
Fig. 1. Patient disposition. aRandomization stratiﬁed by age (<65, 65 years), presence/absence NP. ITT, intent to
treat; AE, adverse event; SS, serum sodium; PV, post-void residual volume.
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(P < 0.0001) and 50 mg (P ¼ 0.02) (Table II). Signiﬁcant mean
decreases were observed by Day 8 with doses of 25 mg
(P ¼ 0.03, 0.0011, <0.0001, respectively), demonstrating a rapid
onset of effect.
When primary endpoints were analyzed by gender
(Table II), the mean change in females was signiﬁcant versus
placebo for 100 mg (P < 0.0001), 50 mg (P ¼ 0.009), and 25 mg
(P ¼ 0.02). For males, 100 mg was superior to placebo (P ¼ 0.005).
TABLE I. Baseline Demographics (Part I)
Demographic characteristic Placebo (n ¼ 156)
Desmopressin orally disintegrating tablet
10 mg (n ¼ 155) 25 mg (n ¼ 152) 50 mg (n ¼ 148) 100 mg (n ¼ 146)
Age (years)
Mean (SD) 62.1 (13.4) 61.7 (14.4) 62.4 (13.2) 61.6 (11.8) 62.1 (12.3)
Sex, n (%)
Female 66 (42%) 73 (47%) 65 (43%) 71 (48%) 66 (45%)
Male 90 (58%) 82 (53%) 87 (57%) 77 (52%) 80 (55%)
Race, n (%)
Caucasian 136 (87%) 123 (79%) 120 (79%) 119 (80%) 111 (76%)
Black/African American 16 (10%) 21 (14%) 28 (18%) 24 (16%) 27 (18%)
Asian 3 (2%) 2 (1%) 2 (1%) 3 (2%) 6 (4%)
Other 1 (1%) 9 (6%) 2 (2%) 2 (1%) 2 (1%)
Baseline number of voidsa, Mean (SD) 3.27 (1.16) 3.21 (1.03) 3.35 (1.32) 3.39 (1.07) 3.22 (1.10)
Presence of nocturnal polyuria, n (%) 142 (91.0) 137 (88.4) 139 (91.4) 135 (91.2) 130 (89.0)
Ever diagnosed with OAB? (% of treatment group) 29 25 24 27 34
Ever diagnosed with BPH? (% of treatment group) 53 45 41 53 51
aOverall, 54% of subjects averaged 3 nocturnal voids, 28% averaged >3–4 nocturnal voids, 11% averaged >4–5 nocturnal voids.
TABLE II. Change From Baseline to Final Visit (Day 28) in: Mean Number of Nocturnal Voids, Duration of First Period of Sleep, Nocturnal and Total Urine
Volume; Also the Proportion of Subjects With >33% Reduction From Baseline to Final Visit (Day 28) (Responder Rate Is Rate Only, Not a Change Score);
All Categories Analyzed Overall and by Gender
Endpoint
All Women Men
n mean SD P n mean SD P n mean SD P
Nocturnal voids
Pbo 156 0.86 1.05 — 66 0.88 1.01 — 90 0.84 1.09 —
10 mg 155 0.83 1.07 0.93 73 1.15 1.07 0.07 82 0.54 0.99 0.09
25 mg 152 1.00 1.13 0.31 65 1.22 1.06 0.02 87 0.83 1.15 0.6
50 mg 148 1.18 1.19 0.02 71 1.23 1.06 0.009 77 1.13 1.3 0.4
100 mg 146 1.43 1.22 <0.0001 66 1.51 1.14 <0.0001 80 1.38 1.28 0.005
33% Responder rate, n (%)
Pbo 156 73 (47) — — 66 28 (42) — — 90 45 (50) — —
10 mg 155 73 (47) — 0.94 73 41 (56) — 0.09 82 32 (39) — 0.2
25 mg 152 76 (50) — 0.55 65 40 (62) — 0.02 87 36 (41) — 0.2
50 mg 148 79 (53) — 0.27 71 42 (59) — 0.04 77 37 (48) — 0.7
100 mg 146 103 (71) — <0.0001 66 51 (77) — <0.0001 80 52 (65) — 0.05
Initial period of undisturbed sleep (minutes)
Pbo 126 39 89 — 49 37 94 — 77 40 86 —
10 mg 126 51 111 0.36 60 54 117 — 66 48 107 —
25 mg 121 83 106 0.001 51 113 118 0.0012 70 61 90 0.18
50 mg 123 85 109 0.0008 61 98 125 0.0048 62 72 90 0.07
100 mg 121 107 116 <0.0001 57 114 130 0.0002 64 100 103 0.0006
Urinary volume, nocturnal (ml)
Pbo 140 109 246 — 66 86 278 — 90 125 219 —
10 mg 137 164 277 0.078 73 207 292 0.011 82 125 257 0.96
25 mg 144 224 264 0.0001 65 307 276 <0.0001 87 163 238 0.15
50 mg 138 272 296 <0.0001 71 257 282 <0.0001 77 286 309 0.0029
100 mg 135 313 275 <0.0001 66 321 239 <0.0001 80 306 302 <0.0001
Urinary volume, total (ml)
Pbo 139 155 427 — 66 127 529 — 90 176 335 —
10 mg 137 220 474 0.37 73 242 481 0.23 82 200 470 0.86
25 mg 142 249 429 0.11 65 350 456 0.019 87 175 396 0.76
50 mg 137 264 515 0.16 71 236 449 0.22 77 290 571 0.49
100 mg 132 346 543 0.0015 66 279 400 0.097 80 398 631 0.0055
Statistically signiﬁcant difference versus Pbo, P  0.05.
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Proportion With >33% Reduction in Mean Number of
Nocturnal Voids
The proportion of subjects with >33% reduction in noctur-
nal voids increased with increasing dose (47–71%) (Table II).
The effect was signiﬁcantly greater versus placebo with
100 mg (P < 0.0001) and demonstrated a rapid onset. In
females, the effect was signiﬁcantly greater versus placebo for
100 mg (P < 0.0001), 50 mg (P ¼ 0.04) and 25 mg (P ¼ 0.02); in
males, 100 mg was superior to placebo (P < 0.05). The results
were consistent in both age groups.
The results of all analyses of voiding data are mutually
supportive, indicating that the MED for desmopressin orally
disintegrating tablets is 100 mg in men and 25 mg in women.
Ten micrograms was sub-therapeutic for the co-primary
endpoints (Table II).
Diuresis (Volumes)
At Day 28, nocturnal urine volume had decreased in all
groups (Table II). Overall reductions were greater in the
treatment groups than with placebo, being signiﬁcant versus
placebo (P < 0.05) at 25–100 mg. For females the difference
was signiﬁcant at 10–100 mg, and for males at 50–100 mg.
Sleep (Time From Falling Asleep to Waking
for First Nocturnal Void)
The initial period of undisturbed sleep increased with
desmopressin dose in all groups (Table II). Increases versus
placebo were signiﬁcant at 25, 50, and 100 mg (83, 85, and
107 min, respectively) (Table II). A signiﬁcant increase was
noted at 25–100 mg in females, and 100 mg in males.
QoL
One less nocturnal void was associated with an increase of
4.68 in total N-QoL score (5.03 for bother/concern, 4.25 for
sleep/energy; P < 0.05) (Table III). Similarly, a 1-hr increase in
ﬁrst period of undisturbed sleep was associated with an
increase of 3.68 in total N-QoL (4.05 for bother/concern score,
3.27 for sleep/energy; P < 0.05) (Table III). These changes sup-
port the notion that reducing nocturia increases QoL.
Safety and Tolerability
AE reporting. Table IV summarizes AE categories by treat-
ment group. The four serious AEs reported were considered
unrelated or unlikely to be related to the study drug and none
were related to reductions in serum sodium. The incidence
of AEs leading to discontinuation was highest in the 50 mg
(8%) and 100 mg (9%) groups, primarily as a result of the
protocol-deﬁned withdrawal of patients with serum sodium
<125 mmol/L. Individual AE terms did not reveal any unex-
pected ﬁndings, with respect to their prevalence. A relation to
desmopressin dose was suggested for the following reported
AEs: ‘‘nausea’’ (<1% in placebo group vs. 2–5% in desmopres-
sin groups), ‘‘diarrhea’’ (1% vs. 1–6%), ‘‘dizziness’’ (0 vs. 2–4%),
‘‘blood sodium decreased’’ (<1% vs. 1–5%), and ‘‘hyponatre-
mia’’ (<1% vs. 0–6%).
Laboratory serum sodium levels. Overall, 24 patients (3.0%)
had serum sodium levels <130 mmol/L during the study. Of
these, nine (1.1% of total), including six women and two men
on active treatment, had reductions in serum sodium to
<125 mmol/L. These drops all occurred within a week of
treatment initiation. Patients 65 years were more frequently
affected than those <65 years (Table V). No woman receiving
25 mg desmopressin had serum sodium <125 mmol/L.
No man under the age of 65 years had serum sodium
<130 mmol/L.
DISCUSSION
The objectives of this large randomized trial were to investi-
gate whether a new formulation of desmopressin was superior
TABLE III. Change in N-QoL for Each Reduction of One in Number of Nocturnal Voids and for Each Increase of 1 hr in First Period of Undisturbed Sleep
Change in N-QoL for each change
of 1 in number of nocturnal voids
estimate [95% CI]
Change in N-QoL for each change of
1 hr in first period of undisturbed
sleep ESTIMATE [95% CI]
Sleep/energy domain 4.25 [3.11; 5.38] 3.27 [2.52; 4.03]
Bother/concern domain 5.03 [3.82; 6.24] 4.05 [3.25; 4.85]
Total score 4.68 [3.61; 5.75] 3.68 [2.98; 4.38]
Statistically signiﬁcant (P  0.05, 95% CI does not contain 0).
TABLE IV. Summary of Treatment-Emergent Adverse Events
Placebo
Active
10 mg 25 mg 50 mg 100 mg Total
n 160 163 158 158 160 799
All AEs, n (%) 76 (48%) 92 (56%) 78 (49%) 92 (59%) 99 (62%) 437 (55%)
Serious AEs, n (%) 1 (<1%)a 1 (<1%)b 1(<1%)c 1 (<1%)d — 4 (<1%)
AEs leading to discontinuation, n (%) 7 (4%) 6 (4%) 2 (1%) 13 (8%) 14 (9%) 42 (5%)
Severe AEs, n (%) 2 (1%) 6 (4%) 3 (2%) 11 (7%) 7 (4%) 29 (4%)
ADRs, n (%) 47 (29%) 55 (34%) 57 (36%) 69 (44%) 73 (46%) 301 (38%)
aProstate cancer.
bDiverticulitis.
cMyalgia.
dMetastasis.
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to placebo for treating nocturia and if the treatment was well
tolerated.
Overall, the highest doses of desmopressin gave rapid, clini-
cally relevant, and statistically signiﬁcant reductions in mean
number of nocturnal voids versus placebo. Dose-dependent
increases in the proportions of patients achieving >33%
reduction in mean number of night voids and decreases
in diuresis were also observed. Importantly, desmopressin
25–100 mg was associated with statistically signiﬁcant
increases in duration of initial sleep period versus placebo,
which amounted to an additional 44–68 min of uninterrupted
sleep per night. The 10 mg dose had a notable (although less
pronounced in men) pharmacodynamic effect on nocturnal
urine production, but this did not translate into improvement
in nocturia over placebo, probably because the lower dose is
insufﬁcient to address all factors involved in the etiology of
nocturia. Reductions in nocturnal diuresis in the placebo
group suggest that patients were following advice to limit ﬂu-
ids and empty their bladder at bedtime.
The safety data obtained in this study are generally
consistent with that from studies with the solid desmopressin
tablet14–18 and support previous ﬁndings that hyponatraemia
is the only safety issue with desmopressin. Age 65 years and
higher desmopressin dosing are predictors of clinically signiﬁ-
cant drops in serum sodium. It is therefore recommended that
only patients with normal serum sodium at baseline should
be treated. Treatment should be discontinued if serum sodium
drops below 130 mmol/L. A phase III study is currently inves-
tigating doses that provide an optimal risk–beneﬁt proﬁle in
elderly males.
A supplemental analysis revealed that females were
more sensitive to desmopressin than males. Doses of 25 mg
upwards were signiﬁcantly superior (P  0.05) to placebo for
both primary efﬁcacy endpoints in females, whereas a statisti-
cally signiﬁcant reduction was only achieved with the 100 mg
dose in males. This suggests MEDs of 25 mg for females and
100 mg for males (since results for all analyses are mutually
supportive). These doses, which are lower than those required
with desmopressin tablets, are supported by the safety analy-
ses, which found no hyponatremia at the MED in women. In
males 65 years, additional monitoring is recommended on
Days 419 and 28 following treatment initiation. The reasons
for this gender effect are not fully understood. Sex-speciﬁc
hormonal mechanisms may alter sensitivity to vasopressin,
and possibly, also to desmopressin.20–22 Alternatively, since
the relevant vasopressin receptor gene (AVPR2) is located on
the X chromosome, it is possible that it is one of few X-linked
genes to escape X inactivation,23 meaning females have
higher levels of AVPR2 expression, and increased response to
desmopressin than males24. This hypothesis requires further
investigation.25
A decrease of one nocturnal void was associated with a
statistically signiﬁcant increase of 5 in total N-QoL score.
This is a relatively new questionnaire, and the extent of
clinically relevant changes in score has not been established.
A few studies have indicated differences in N-QoL score of
between 2.9 and 11 for each void/night.4,19,26 Our ﬁndings are
comparable with these scores.
Nocturia is acknowledged to be a nontrivial condition that
can have serious effects on patients’ morbidity, mortality and
QoL.27 The ﬁndings of this study not only support the efﬁcacy
and safety ﬁndings of previous studies with desmopressin in
nocturia, but also indicate areas of research to further opti-
mize the risk–beneﬁt ratio for the drug in patients of both
genders and all ages.
CONCLUSIONS
Desmopressin orally disintegrating tablet is a well-tolerated
and effective treatment for nocturia. It prolongs the ﬁrst sleep
period and thereby improves patients’ QoL. Early monitoring
is recommended in males aged 65 years due to increased
risk of serum sodium reductions with age and higher dosing.
Further risk–beneﬁt analyses are required to conﬁrm the MED
ﬁndings and any advantages of moving to a lower recom-
mended dose based on them.
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